The expertise of Dr. K Oberg ranks in the
- Top 0.019%
- ... of 88,969 published authors worldwide on Pancreatic Neoplasms
- ... from 2007 through 2018
- ... based on contributions to
36 articles
on the topic.
Graphical view (beta)
Hide
Longer horizontal black lines means more people have that level of expertise.
Expertise level forDr. K Oberg |
|
|
|
|
Higher
Amount of
expertise
(logarithmic)
Lower
|
|
Uncounted papers?
Get your prestigious
World Expert badge
similar to this:
|
|
Oberg, K · Oberg, Kjell · Oberg, Kjell E · Öberg, Kjell E · Öberg, Kjell · Öberg, K
|
Confirmed:
(Apr. 2015) |
|
|
Uppsala University |
|
|
|
| 2016 | - Department of Surgery, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06519, USA. · Department of Endocrine Oncology, Uppsala University Hospital, Entrance 40, 5th floor, SE-751 85 Uppsala, Sweden. · Pubmed 27273044
|
| 2015 | - Department of Endocrine Oncology, Uppsala University Hospital , Entrance 40, 5th floor, SE-751 85 Uppsala , Sweden. · Pubmed 25855088
|
| 2013 | - Department of Endocrine Oncology, University Hospital of Uppsala, Sweden. · Pubmed 23296177
- Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 23391111
|
| 2012 | - Department of Endocrine Oncology, University Hospital, Uppsala University, Uppsala, Sweden. · Pubmed 22997445
- Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 23582922
- Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden. · Pubmed 22510940
|
| 2011 | - Department of Endocrine Oncology, University Hospital, Entrance 78, SE-751 85 Uppsala, Sweden. · Pubmed 22005113
|
| 2010 | - Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 20555086
- Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 21167379
- Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 20637207
|
| 2009 | - Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 19454440
- Department of Endocrine Oncology, University Hospital, SE-751 85 Uppsala, Sweden. · Pubmed 19445573
- Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 19115524
|
| 2008 | - Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 18456741
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
| 2011 | - Department of Endocrine Oncology, Uppsala University Hospital, Sweden. · Pubmed 22009449
|
| 2010 | - Department of Medical Sciences, Uppsala University, Uppsala, Sweden. · Pubmed 20553100
- Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 20100145
- Department of Endocrine Oncology, University Hospital, S-751 85 Uppsala, Sweden. · Pubmed 20150630
|
| 2009 | - Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, 751 85 Uppsala, Sweden. · Pubmed 19381631
|
| 2008 | - Department of Oncology, Uppsala University, Uppsala, Sweden. · Pubmed 18285678
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden. · Pubmed 19047107
- Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, Uppsala, Sweden. · Pubmed 18376130
|
| 2007 | - Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 17873310
- Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. · Pubmed 17438105
|
|
Show MoreFewer
| Probable: |
|
|
Miscellaneous cities in Sweden |
|
|
|
| 2016 | - University HospitalUppsala, Sweden · Erasmus Medical CenterRotterdam, The Netherlands. · Pubmed 27697899
|
|
| Possible: |
|
|
University of Texas Houston |
Contact |
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
| 2011 | - Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA. · Pubmed 21994954
- University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 21306238
|
|
| Possible: |
|
|
Charite-Universitatsmedizin |
|
|
|
| 2016 | - Charite Virchow Klinikum, Berlin, Germany. · Pubmed 26731013
- James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Hospices Civils de Lyon |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
University of Basel |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Mayo Clinic Rochester |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Katholieke Universiteit Leuven |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Universitat Autonoma de Barcelona |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Universitat de Barcelona |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
University of Groningen |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
University of Bologna |
|
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Oregon Health Sciences University |
Contact |
|
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
| Possible: |
|
|
Miscellaneous institutions in Udine |
|
|
|
| 2014 | - Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia", P.le S.M. della Misericordia, 15-33100, Udine, Italy, · Pubmed 25038902
|
|
| Possible: |
|
|
University College London |
|
|
|
| 2014 | - Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK. · Pubmed 24458014
|
|
| Possible: |
|
|
University of Athens |
|
|
|
| 2012 | - Department of Pathophysiology (Endocrine Unit), University of Athens Medical School, Mikras Asias 75, 11527, Athens, Greece. · Pubmed 22319031
|
|
| Possible: |
|
|
Yale University |
Contact |
|
|
| 2010 | - School of Medicine, Yale University, New Haven, Conn, USA. · Pubmed 20618115
|
| 2008 | - Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520-8062, USA. · Pubmed 18177818
|
|
| Possible: |
|
|
Miscellaneous institutions in Sao Paulo |
|
|
|
|
|
|
In the titles of their published articles, experts often reveal their very specific interests.
Here
are the titles of the 10 most recent articles
(out of 36 total) written by Dr. K Oberg
about Pancreatic Neoplasms:
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. 2016
- Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. 2016
- Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. 2016
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. 2016
- Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view. 2015
- Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. 2014
- Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. 2014
- Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy. 2013
- The genetics of neuroendocrine tumors. 2013
- Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012
Show List of Full Article Records
|
|
Learn more about Dr. K Oberg using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!
| General Search: |
|
| Uppsala University |
|
|
|
What is this?
|
|
|
|
Uppsala University
|
| | |
|
| 2016 | - Department of Surgery, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06519, USA. · Department of Endocrine Oncology, Uppsala University Hospital, Entrance 40, 5th floor, SE-751 85 Uppsala, Sweden. · Pubmed 27273044
|
| 2015 | - Department of Endocrine Oncology, Uppsala University Hospital , Entrance 40, 5th floor, SE-751 85 Uppsala , Sweden. · Pubmed 25855088
|
| 2013 | - Department of Endocrine Oncology, University Hospital of Uppsala, Sweden. · Pubmed 23296177
- Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 23391111
|
| 2012 | - Department of Endocrine Oncology, University Hospital, Uppsala University, Uppsala, Sweden. · Pubmed 22997445
- Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 23582922
- Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden. · Pubmed 22510940
|
| 2011 | - Department of Endocrine Oncology, University Hospital, Entrance 78, SE-751 85 Uppsala, Sweden. · Pubmed 22005113
|
| 2010 | - Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 20555086
- Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 21167379
- Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 20637207
|
| 2009 | - Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 19454440
- Department of Endocrine Oncology, University Hospital, SE-751 85 Uppsala, Sweden. · Pubmed 19445573
- Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 19115524
|
| 2008 | - Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 18456741
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
| 2011 | - Department of Endocrine Oncology, Uppsala University Hospital, Sweden. · Pubmed 22009449
|
| 2010 | - Department of Medical Sciences, Uppsala University, Uppsala, Sweden. · Pubmed 20553100
- Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 20100145
- Department of Endocrine Oncology, University Hospital, S-751 85 Uppsala, Sweden. · Pubmed 20150630
|
| 2009 | - Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, 751 85 Uppsala, Sweden. · Pubmed 19381631
|
| 2008 | - Department of Oncology, Uppsala University, Uppsala, Sweden. · Pubmed 18285678
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden. · Pubmed 19047107
- Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, Uppsala, Sweden. · Pubmed 18376130
|
| 2007 | - Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden. · Pubmed 17873310
- Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. · Pubmed 17438105
|
|
|
|
|
Miscellaneous cities in Sweden
|
| | |
|
| 2016 | - University HospitalUppsala, Sweden · Erasmus Medical CenterRotterdam, The Netherlands. · Pubmed 27697899
|
|
|
|
|
16 Other Locations
Show
Hide
|
| | |
|
|
|
| Yearly article counts |
0 | 0 | 4 | 1 | 2 | 2 | 4 | 4 | 7 | 4 | 6 | 2 |
|
|
|
|
University of Texas Houston
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
| 2011 | - Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA. · Pubmed 21994954
- University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 21306238
|
|
|
|
|
Charite-Universitatsmedizin
|
| | |
|
| 2016 | - Charite Virchow Klinikum, Berlin, Germany. · Pubmed 26731013
- James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Hospices Civils de Lyon
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
University of Basel
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Mayo Clinic Rochester
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Katholieke Universiteit Leuven
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Universitat Autonoma de Barcelona
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Universitat de Barcelona
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
University of Groningen
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
University of Bologna
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Oregon Health Sciences University
|
| | |
|
| 2016 | - James C. Yao, University of Texas MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Wei He, and David Chen, Novartis, East Hanover, NJ; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Rodney Pommier, Oregon Health & Science University, Portland, OR; Marianne Pavel, Charité Universitätsmedizin, Berlin, Germany; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Eric Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium; Ulrike Brandt, Novartis Pharma AG, Basel, Switzerland; Jaume Capdevila, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Elisabeth G. E. de Vries, UMCG, University of Groningen, Groningen, Netherlands; Paola Tomassetti, University of Bologna, Bologna, Italy; and Kjell Öberg, Uppsala University Hospital, Uppsala, Sweden. · Pubmed 27621394
|
|
|
|
|
Miscellaneous institutions in Udine
|
| | |
|
| 2014 | - Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia", P.le S.M. della Misericordia, 15-33100, Udine, Italy, · Pubmed 25038902
|
|
|
|
|
University College London
|
| | |
|
| 2014 | - Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK. · Pubmed 24458014
|
|
|
|
|
University of Athens
|
| | |
|
| 2012 | - Department of Pathophysiology (Endocrine Unit), University of Athens Medical School, Mikras Asias 75, 11527, Athens, Greece. · Pubmed 22319031
|
|
|
|
|
Yale University
|
| | |
|
| 2010 | - School of Medicine, Yale University, New Haven, Conn, USA. · Pubmed 20618115
|
| 2008 | - Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520-8062, USA. · Pubmed 18177818
|
|
|
|
|
Miscellaneous institutions in Sao Paulo
|
| | |
|
|
|
| Yearly article counts |
0 | 0 | 4 | 1 | 2 | 2 | 4 | 4 | 7 | 4 | 6 | 2 |
|
|
You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape
"Saved Pages" page, which is always easily available
from the page-top menu bar throughout the site.
|
